Data Collective IV GP, LLC

13F filer · CIK 0001664974

Reported Aug 14, 2026

13F portfolio value$78.6MU.S. long equity reported on 13F

Positions40 new · 0 closed

Net flow last quarter$0Buys minus sells

Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free

Scroll for earlier quarters

Company	Value	% of portfolio	% of company	POSITION CHANGE qoq %	First reported
Q2 2026Reported Aug 14, 20264 positions
EVLVEvolv Technologies Holdings, Inc.	$26.6M	33.89%	2.54%	Not reported	Q4 2021
HQHorizon Quantum Holdings Ltd.	$25.4M	32.34%	91519800.00%	Not reported	Q1 2026
RXRXRecursion Pharmaceuticals, Inc.	$21.8M	27.76%	1.11%	Not reported	Q4 2021
DFTXDefinium Therapeutics, Inc.	$4.72M	6.01%	0.07%	Not reported	Q1 2026
Q1 2026Reported May 15, 20264 positions
EVLVEvolv Technologies Holdings, Inc.	$27.8M	49.63%	2.56%	Not reported	Q4 2021
RXRXRecursion Pharmaceuticals, Inc.	$18.2M	32.60%	1.12%	Not reported	Q4 2021
HQHorizon Quantum Holdings Ltd.	$8.04M	14.38%	91519800.00%	New	Q1 2026
DFTXDefinium Therapeutics, Inc.	$1.9M	3.39%	0.10%	New	Q1 2026
Q4 2025Reported Feb 17, 20263 positions
EVLVEvolv Technologies Holdings, Inc.	$32.9M	56.17%	2.62%	-8.2%	Q4 2021
RXRXRecursion Pharmaceuticals, Inc.	$24.3M	41.53%	1.12%	Not reported	Q4 2021
MNMDDefinium Therapeutics, Inc.	$1.34M	2.30%	Not reported	Not reported	Q4 2021
Q3 2025Reported Nov 14, 20254 positions
EVLVEvolv Technologies Holdings, Inc.	$37.8M	55.53%	2.88%	-48.4%	Q4 2021
RXRXRecursion Pharmaceuticals, Inc.	$29M	42.65%	1.21%	Not reported	Q4 2021
MNMDDefinium Therapeutics, Inc.	$1.18M	1.74%	Not reported	Not reported	Q4 2021
ROIVRoivant Sciences Ltd.	$58.6K	0.09%	0.00%	Not reported	Q4 2022

Premium opens every quarter this fund has filed